|
|
Development of a Fluorescence Polarization Assay for the Molecular Chaperone Hsp90
Joungnam Kim
Program in Cell Biology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Sara Felts
Department of Biochemistry and Molecular Biology, Mayo College of Medicine, Rochester, MN 55905.
Laura Llauger
Program in Cell Biology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Huazhong He
Program in Cell Biology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Henri Huezo
Program in Cell Biology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Neal Rosen
Program in Cell Biology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Gabriela Chiosis
Program in Cell Biology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Heat shock protein 90 (Hsp90) is a molecular chaperone with essential functions in maintaining transformation, and there is increasing interest in developing Hsp90 inhibitors as cancer therapeutics. In this study, the authors describe the development and optimization of a novel assay for the identification of Hsp90 inhibitors using fluorescence polarization. The assay is based on the competition of fluorescently (BODIPY) labeled geldanamycin (GM) for binding to purified recombinant Hsp90 (GM is a natural product that binds to the ATP/ADP pocket in the amino terminal of Hsp90). The authors show that GM-BODIPY binds Hsp90 with high affinity. Even at low Hsp90 concentrations (30 nM), the measured polarization value is close to the maximum assay range of 160 mP, making measurements very sensitive. Its performance, as judged by signal-to-noise ratios (> 10) and Z and Z' values (> 0.5), suggests that this is a robust and reliable assay. GM, PU24FCl, ADP, and ATP, all known to bind to the Hsp90 pocket, compete with GM-BODIPY for binding to Hsp90 with EC50s in agreement with reported values. These data demonstrate that the Hsp90-FP-based assay can be used for high-throughput screening in aiding the identification of novel Hsp90 inhibitors.
Key Words: fluorescence polarization Hsp90 competitive assay high-throughput screening
Journal of Biomolecular Screening, Vol. 9, No. 5,
375-381 (2004)
DOI: 10.1177/1087057104265995

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Lundgren, H. Zhang, J. Brekken, N. Huser, R. E. Powell, N. Timple, D. J. Busch, L. Neely, J. L. Sensintaffar, Y.-c. Yang, et al.
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
Mol. Cancer Ther.,
April 1, 2009;
8(4):
921 - 929.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Yuhong Du, K. Moulick, A. Rodina, J. Aguirre, S. Felts, R. Dingledine, Haian Fu, and G. Chiosis
High-Throughput Screening Fluorescence Polarization Assay for Tumor-Specific Hsp90
J Biomol Screen,
October 1, 2007;
12(7):
915 - 924.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. T. Gooljarsingh, C. Fernandes, K. Yan, H. Zhang, M. Grooms, K. Johanson, R. H. Sinnamon, R. B. Kirkpatrick, J. Kerrigan, T. Lewis, et al.
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues
PNAS,
May 16, 2006;
103(20):
7625 - 7630.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|